Evaluation of over 10 million insurance claims in the USA provides evidence of “adverse selection” in the prescription of opioids.
Pharmacoepigenetics of the role of DNA methylation in μ-opioid receptor expression in different human brain regions
In the study, the authors investigated a possible association between differential μ-opioid receptor expression across several brain areas and varying degrees of OPRM1 DNA methylation.
In a study from Toronto Western Hospital (TO, Canada), researchers have conducted an analysis of health care data to measure the time of opioid cessation after prescription following major surgery.
In this interview, Dr Clarke discusses his recent paper in Pain Management, ‘Chronic postsurgical pain and persistent opioid use following surgery: the need for a transitional pain service’.
New research from Johns Hopkins Medicine (MD, USA) suggests patients who undergo long-term opioid therapy for pain management of sickle cell disease may fare worse than those who do not.
Webinar Q&A follow-up: Manipulation of Abuse Deterrent Formulations at the Clinical Pharmacology Unit
Read the Q&A transcript and responses to the unanswered questions from our webinar on ‘Manipulation of Abuse Deterrent Formulations at the Clinical Pharmacology Unit’.
Probuphine, the first buprenorphine implant designed for the maintenance treatment of opioid dependence has been approved by the U.S. FDA.
What is the opioid epidemic? What has caused it? How can we fix it? Pain expert Michael Schatman discusses.
A University of Chicago (IL, USA) research team has shed further light on the impact of the current ‘opioid epidemic’ taking place in the USA after analyzing national trends in intensive care unit (ICU) admissions related to opioid overdoses.